Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OSBP | P22059 | 1/20 | 0.78 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.76 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.75 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.74 |
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.72 |
| ▸ | CASP7 | P55210 | 3/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | VDR | P11473 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.72 |
| ▸ | MDM4 | O15151 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epicoprosterol SCHEMBL11375007 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL18724866 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL9906585 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL24632942 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL12549295 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL25267973 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL12214992 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL21000320 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL22018677 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 | |
| Epicoprosterol SCHEMBL11381925 | 1.00 | OSBP (0.78) | OSBPOSBP2CYP2C19CYP2D6ST6GAL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332494-B2 | Nanoemulsions and methods for cancer therapy | FERNANDO THOME KREUTZ (BR) | 2022-05-17 | — | — | US | disclosed |
| EP-2625190-B1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC, ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | UNIV JUSTUS LIEBIG GIESSEN (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-20190144492-A1 | NANOEMULSIONS AND METHODS FOR CANCER THERAPY | KREUTZ FERNANDO THOME (BR) | 2019-05-16 | — | — | US | disclosed |
| US-9382288-B2 | Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2016-07-05 | — | — | US | disclosed |
| US-9382288-B2 | Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20130266645-A1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2013-10-10 | — | — | US | disclosed |
| US-20130266645-A1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2013-10-10 | — | — | US | disclosed |
| WO-2012051988-A2 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC, ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052821-A1 | LIGHT INDUCED DRUG RELEASE | UNIVERSITEIT LEIDEN (NL) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332494-B2 | Nanoemulsions and methods for cancer therapy | NR1H3, OSBPL3, CYP46A1 | OSBP 6/4885OSBP2 8/4885CYP2C19 2267/4885 |
| US-20190144492-A1 | NANOEMULSIONS AND METHODS FOR CANCER THERAPY | NR1H3, OSBPL3, CYP46A1 | OSBP 6/4885OSBP2 8/4885CYP2C19 2267/4885 |
| US-20130266645-A1 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION | HSD17B7, CYP21A2, CYP17A1 | OSBP 1029/4885OSBP2 2253/4885CYP2C19 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.